A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions

P

Paddock Laboratories

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Drug: Univasc® 15mg Tablets
Drug: Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.

Study type

Interventional

Funder types

Industry

Identifiers

NCT00992862
B035302

Details and patient eligibility

About

The purpose of this study is to compare the relative bioavailability of Moexipril HCl 15mg tablets (by Paddock Laboratories, Inc.) with that of Univasc® 15mg tablets (by Schwarz Pharma) following a single oral dose (1 x 15mg tablet) in healthy, adult subjects under fasting conditions.

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Good health as determined by lack of clinically significant abnormalities in health assessment performed at screening

Exclusion criteria

  • Positive test results for HIV or Hepatitis B or C
  • History of allergy or sensitivity to Moexipril HCl or related drugs

Trial design

60 participants in 2 patient groups

Moexipril HCl 15mg Tablets
Experimental group
Treatment:
Drug: Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.
Univasc® 15mg Tablets
Active Comparator group
Treatment:
Drug: Univasc® 15mg Tablets

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems